Combined inhibition of Bcl2 and Bcr-Abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells
M Massimino, P Vigneri, S Stella, E Tirrò… - Journal of Clinical …, 2021 - mdpi.com
Background: The management of Philadelphia Chromosome-positive (Ph+) hematological
malignancies is strictly correlated to the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) …
malignancies is strictly correlated to the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) …